Individuals with diabetes are not only at high risk of developing heart failure but are also at
increased risk of dying from it. Fortunately, antiheart failure therapies such as angiotensin …

Objectives To examine the association between dipeptidyl peptidase-4 (DPP-4) inhibitors
and the risk of heart failure or hospital admission for heart failure in patients with type 2 …

Члены Комитета экспертов подтвердили отсутствие финансовой поддержки/конфликта
интересов. В случае сообщения о наличии конфликта интересов, член (ы) Комитета …

Importance Abnormal cardiac metabolism contributes to the pathophysiology of advanced
heart failure with reduced left ventricular ejection fraction (LVEF). Glucagon-like peptide 1 …

Background The EXAMINE trial showed non-inferiority of the DPP-4 inhibitor alogliptin to
placebo on major adverse cardiac event (MACE) rates in patients with type 2 diabetes and …

Guidelines RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2
Diabetes Mellitus 2020Table. No title available.

Background Some glucose-lowering drugs or strategies adversely affect cardiovascular
outcomes. We aimed to assess the extent to which glucose lowering by various drugs or …

Aims To report the cardiovascular (CV) safety profile and heart failure (HF) risk of vildagliptin
from a large pool of studies, including trials in high‐risk patients with type 2 diabetes mellitus …

Elevated plasma triglyceride (TG) concentrations are associated with an increased risk of
atherosclerotic cardiovascular disease (CVD), hepatic steatosis and pancreatitis. Existing …

Diabetes mellitus increases the risk of developing heart failure, and the co-existence of both
diseases worsens cardiovascular outcomes, hospitalization, and the progression of heart …